Prurigo Nodularis
Prurigo Nodularis Market

Prurigo Nodularis (PN) is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. PN is accompanied by long-standing pruritus and thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo (CP) from various etiologies, including dermatological, systemic, infectious, and psychiatric.


The disease is characterized by hyperkeratotic, crusted or excoriated, light-red to bright-red papules, nodules or plaques with hyperpigmented margins as a distinguish features.


Prurigo Nodularis Epidemiological Segmentation 

The Epidemiological Segmentation of Prurigo Nodularis in 7MM from 2017 to 2030 is segmented as:- 

• Diagnosed Prevalent Cases

• Gender-specific Diagnosed Prevalence

• Age-specific Diagnosed Prevalence

• Type-specific Diagnosed Prevalence

• Severity-specific Diagnosed Prevalence


Prurigo Nodularis Epidemiology 

• The total diagnosed prevalent population in 7MM in 2017 was 539,893  

• The United States had the largest share of the total diagnosed prevalent population with ~46.30% of the total cases in 2017

• EU5 countries occupied 38.31% of the patient pool amongst 7MM in 2017


Prurigo Nodularis Market

The market size of Prurigo Nodularis in 7MM in 2017 was USD 659.29 Million 


Prurigo Nodularis Market Drivers

• Government Initiatives

• Pipeline Advancements and various off-label therapies

• Growth in R&D 

• Increase in the number of patients 


Prurigo Nodularis Market Barriers

• Disease-related challenges in terms of pathophysiology and management

• Lack of Clinical Trial Data


Prurigo Nodularis Emerging Drugs

The emerging drugs of the Prurigo Nodularis market are 

• Serlopitant

• Nalbuphine ER

• Nemolizumab (CD14152)

• Apremilast (CC-10004)

• M 118103

• KPL-716

• Dupixent (Dupilumab/SAR231893)

And many others. 


Prurigo Nodularis Key Players

The key players in the Prurigo Nodularis market are

• Menlo Therapeutics

• Trevi Therapeutics

• Galderma

• Amgen

• Maruho

• Kiniksa Pharmaceuticals

• Sanofi

• Regeneron Pharmaceuticals

And many others.